Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.

ESMO Open 2017 11;2(1):e000102. Epub 2017 Apr 11.

Boehringer Ingelheim Pharmaceuticals GmbH & Co. KG, Biberach, Germany.

Introduction: No predictive clinical or genetic markers have been identified or validated for antiangiogenic agents in lung cancer. We aimed to identify a predictive clinical marker of benefit for nintedanib, an angiokinase inhibitor, using data from two large second-line non-small cell lung cancer Phase III trials (LUME-Lung 1 ([LL1] and LUME-Lung 2).

Methods: Predictive marker identification was conducted in a multi-step process using data from both trials; a hypothesis was generated, confirmed and validated. Statistical analyses included a stepwise selection approach, a recursive partitioning method and the evaluation of HRs, including treatment-by-covariate interactions. The marker was finally validated using a prospectively defined hierarchical testing procedure and treatment-by-covariate interaction for overall survival (OS) based on LL1.

Results: Time since start of first-line therapy (TSFLT) was identified as the only predictive clinical marker. A cut-off of 9 months was chosen for further analysis, based on HRs and recursive partitioning. The prospectively defined final validation using OS data from LL1 established the strong relationship between TSFLT and treatment with nintedanib. Patients with adenocarcinoma with TSFLT <9 months showed a greater survival benefit (median OS 10.9 vs 7.9 months, HR 0.75 [95% CI 0.60-0.92]; p=0.0073) compared with patients in the TSFLT >9 months group (median OS 17.0 vs 15.1 months, HR 0.89 [95% CI 0.66-1.19]).

Conclusions: Patients with shorter TSFLT derive a greater progression-free survival and OS benefit from nintedanib. This clinical marker could be used for patient selection and further investigation is warranted regarding pathways promoting aggressive tumour growth and antiangiogenic tyrosine kinase inhibitor benefit.

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519785PMC
April 2017
27 Reads

Publication Analysis

Top Keywords

clinical marker
16
predictive clinical
16
lung cancer
12
nintedanib patients
8
prospectively defined
8
time start
8
benefit nintedanib
8
cell lung
8
start first-line
8
non-small cell
8
first-line therapy
8
recursive partitioning
8
marker
6
clinical
5
predictive
5
treatment nintedanib
4
analyses included
4
included stepwise
4
stepwise selection
4
patients adenocarcinoma
4

References

(Supplied by CrossRef)

Similar Publications